Trial Profile
A Single-arm Evaluation of the Effect of Elbasvir/Grazoprevir on Cardiometabolic Parameters in Patients With Hepatitis C Infection and Underlying Metabolic Disease
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Acronyms HEART-C
- 03 Aug 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 19 Jul 2018 New trial record